Unsung hero
Baj Singh
Baj Singh migrated to America and gathered a large number of immigrants to join the freedom movement. He was an active member of the Ghadar Movement and faced rigorous imprisonment upon his return to India.
Bafna Pharmaceuticals Ltd
₹ 258
-2.00%
14 Aug
- close price
About
Incorporated in 1981, Bafna Pharmaceuticals
Ltd manufactures finished pharmaceutical formulations[1]
Key Points
- Market Cap ₹ 610 Cr.
- Current Price ₹ 258
- High / Low ₹ 296 / 91.2
- Stock P/E 78.3
- Book Value ₹ 40.6
- Dividend Yield 0.00 %
- ROCE 11.9 %
- ROE 12.3 %
- Face Value ₹ 10.0
Unsung hero
Ligin Bomjen
In 1943, the British had banned the salt trade. Ligin and his friends smuggled salt to their village. He also served as a porter during World War II.
Pros
Cons
- Stock is trading at 6.34 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 9.88% over last 3 years.
- Earnings include an other income of Rs.6.07 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 | 85 | 65 | 46 | 44 | 42 | 71 | 85 | 115 | 152 | 146 | 151 | 143 | |
| 116 | 82 | 70 | 81 | 57 | 41 | 61 | 73 | 100 | 141 | 135 | 135 | 131 | |
| Operating Profit | -16 | 3 | -5 | -35 | -13 | 1 | 10 | 12 | 16 | 11 | 11 | 16 | 12 |
| OPM % | -16% | 3.3% | -8% | -77% | -30% | 2.9% | 14% | 14% | 14% | 7% | 8% | 11% | 8% |
| 40 | 1 | 1 | 31 | 0 | -23 | 1 | -0 | 3 | 4 | 1 | 5 | 6 | |
| Interest | 12 | 12 | 11 | 7 | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 4 | 4 |
| Depreciation | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 6 | -13 | -19 | -14 | -18 | -25 | 6 | 5 | 12 | 7 | 4 | 11 | 8 |
| Tax % | -0% | -3% | -4% | 15% | 8% | -0% | -0% | -0% | 2% | -0% | -0% | -1% | |
| 6 | -12 | -18 | -16 | -20 | -25 | 6 | 5 | 11 | 7 | 4 | 11 | 8 | |
| EPS in Rs | 3.28 | -6.53 | -9.90 | -6.95 | -8.34 | -106.53 | 2.46 | 2.21 | 4.79 | 3.11 | 1.75 | 4.69 | 3.29 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 16% |
| 3 Years: | 9% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 0% |
| TTM: | -23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 13% |
| 3 Years: | 34% |
| 1 Year: | 136% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 24 | 24 | 2 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 53 | 41 | 26 | 17 | -3 | 49 | 33 | 38 | 50 | 57 | 61 | 72 |
| 64 | 80 | 82 | 47 | 46 | 3 | 15 | 11 | 23 | 24 | 28 | 37 | |
| 50 | 45 | 40 | 40 | 54 | 17 | 14 | 17 | 33 | 42 | 40 | 42 | |
| Total Liabilities | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 176 |
| 49 | 47 | 43 | 40 | 37 | 35 | 36 | 39 | 40 | 40 | 59 | 82 | |
| CWIP | -0 | -0 | -0 | -0 | -0 | 0 | 1 | -0 | 2 | 12 | 7 | 3 |
| Investments | 18 | 18 | 18 | 1 | 1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| 118 | 120 | 106 | 86 | 82 | 36 | 50 | 51 | 88 | 95 | 87 | 91 | |
| Total Assets | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 176 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | -3 | 14 | -7 | -1 | -34 | -14 | 10 | 5 | 9 | 22 | 15 | |
| 56 | -1 | -8 | 38 | 4 | 33 | -5 | -7 | -7 | -15 | -21 | -22 | |
| -66 | 4 | -5 | -31 | -2 | 7 | 12 | -5 | 10 | -1 | 1 | 6 | |
| Net Cash Flow | -0 | 0 | -0 | 0 | -0 | 6 | -7 | -2 | 8 | -6 | 2 | -1 |
| Free Cash Flow | 2 | -5 | 20 | 40 | -1 | -36 | -20 | 2 | -2 | -6 | 0 | -10 |
| CFO/OP | -74% | -106% | -263% | 20% | 8% | -2,786% | -132% | 83% | 32% | 87% | 194% | 96% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 303 | 291 | 302 | 195 | 208 | 52 | 49 | 63 | 130 | 109 | 101 | 106 |
| Inventory Days | 66 | 92 | 118 | 102 | 122 | 208 | 154 | 185 | 129 | 125 | 127 | 129 |
| Days Payable | 149 | 169 | 164 | 265 | 517 | 229 | 107 | 113 | 165 | 149 | 140 | 139 |
| Cash Conversion Cycle | 220 | 214 | 255 | 31 | -188 | 31 | 96 | 135 | 94 | 84 | 88 | 96 |
| Working Capital Days | 56 | 125 | -36 | -108 | -210 | 89 | 121 | 123 | 104 | 92 | 74 | 74 |
| ROCE % | -13% | -0% | -6% | -35% | -21% | -3% | 10% | 11% | 16% | 9% | 8% | 12% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Pending Product Registration Applications applications |
|
|||||||||
| Total Product Registrations products |
||||||||||
| Number of Countries with Product Registrations countries |
||||||||||
| Export Revenue Share % |
||||||||||
| New Product Registrations (Annual) products |
||||||||||
| Top Customer Concentration % |
||||||||||
| Top Product Concentration % |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' …
-
Book Closure For 31St Annual General Meeting
- 31st AGM on September 11, 2026; book closure September 5-11, 2026; e-voting September 8-10.
- Shareholder Meeting - 31St AGM On September 11, 2026
-
Unaudited Financial Results For The Quarter Ended June 30, 2026
- Q1 FY27 results approved; AGM on Sept 11, 2026; GST orders total Rs 566.56 lakh.
-
Board Meeting Outcome for The Board Meeting Held On 11/08/2026
- Board approved Q1 FY27 results; GST demands of ₹235.47 lakh and ₹331.09 lakh disclosed; AGM on September 11, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
Product Profile:[1][2][3]
Company is manufacturing over 336
licensed pharmaceutical formulations
and has globally registered 78 of its
products viz. Afenac-p Tab, Afenac-th
Tab, finished solid oral and liquid oral
dosage forms of Betalactam and Non – Betalactam and Cephalosporin products